On December 2nd, Beijing welcomed an investment of up to 1 billion euros (approximately 7.66 billion yuan) - the Beijing Municipal Bureau of Economy and Information Technology, the Beijing Economic and Technological Development Zone Management Committee, and multinational pharmaceutical company Sanofi signed a memorandum of cooperation. Sanofi will build a new insulin production base in Yizhuang, and after completion, it will form a full industry chain layout of insulin preparations from raw materials to finished products in Beijing.

Sanofi will invest in the construction of the second Beijing production base, improve the local end-to-end production and manufacturing capacity of insulin, and focus on serving the insulin drug demand of local diabetes patients. This will be Sanofi's fourth production and supply base in China, and also the company's largest single investment in China.

Over the past 40 years of deep cultivation in China, Sanofi has continuously increased its investment in Chinese manufacturing and built a world-class production and supply network. The newly established Beijing insulin production base will work together with the newly expanded Beijing production base last year, as well as the production bases in Shenzhen and Hangzhou, to form Sanofi's high-quality production capacity guarantee in China. It is also an important support for Sanofi's deep participation in the construction of new quality productivity in China's pharmaceutical industry. They will jointly support the daily medication and vaccine needs of patients and the general public in China and surrounding markets.

We are pleased to announce this investment on the occasion of the 60th anniversary of the establishment of diplomatic relations between China and France. Sanofi firmly believes in the long-term development of the Chinese market. The Chinese government's policies of opening up to the outside world and encouraging innovation, as well as the favorable business environment created for foreign-funded enterprises, have injected strong confidence into Sanofi's deep participation in China's economic development and the high-quality development of the pharmaceutical industry, "said Fr é d é ric Oud é a, Chairman of the Board of Directors of Sanofi Group.

Sanofi has been continuously increasing its investment in Made in China to build a world-class production and supply network. In 1982, it established an office in China and currently has 12 diversified offices, 3 production bases, and 4 research and development bases. Its diversified business covers pharmaceuticals, human vaccines, and consumer health. Among them, Sanofi's Beijing production base, located in Beijing Economic and Technological Development Zone, has become Sanofi's largest insulin injection production base in the Asia Pacific region after nearly 30 years of development, and its products cover many fields such as diabetes, cardiovascular, medical and tumor.

The newly established insulin production base is the first time that a multinational pharmaceutical company has laid out the production of biopharmaceutical raw materials in China. After completion, it will mainly produce active substances for insulin biopharmaceuticals and supply biological raw materials for the existing insulin formulation products of Sanofi Beijing factory.
Paul Hudson, Chief Executive Officer of Sanofi, said that the new production base adopts high standards of automated production, first-class digital integrated management, and sustainable environmental protection standards to ensure excellent production standards, which will further help us to enhance the resilience of the supply chain and more efficiently meet the growing needs of local diabetes patients. "We will also continue to deepen the layout of the industrial chain in China, upgrade innovative medical solutions, and continue to improve the depth and breadth of medical services."

From the official establishment of Sanofi's Beijing production base in Yizhuang, Beijing in 1995, to the continuous capital increase of 700 million yuan from 2020 to 2023 to expand the insulin new formulation production line (Laiyoushi and Saiyining projects), and then to the new insulin production base, Sanofi's capital increase and expansion demonstrate recognition of the industrial ecology of Beijing and Yizhuang, as well as confidence in the future development prospects.

The pharmaceutical and health industry is one of the "dual engines" driving innovation and development in Beijing. Since the beginning of this year, Beijing has organized and implemented the third round of the Action Plan to Accelerate Collaborative Innovation in Medicine and Health, introducing 32 measures to support the development of innovative medicine, providing a better development environment for multinational pharmaceutical companies to land and increase investment.

As the only national level economic development zone in the capital, Beijing Economic Development Zone focuses on enhancing its international competitiveness and medical health level in the field of biomedicine, establishing a "1+N" policy system for the biopharmaceutical industry, supporting the landing and aggregation of the six major centers of the National Medical Products Administration, accelerating the planning and construction of the Beijing Pharmaceutical Innovation Park BioPark, improving enterprise services, and cultivating new driving forces for industrial development. Currently, nearly 5000 biopharmaceutical enterprises in various fields have been gathered, and the output value of the biopharmaceutical industry accounts for about half of Beijing's territory.

In order to attract more multinational pharmaceutical companies to set up in Yizhuang, Beijing, we take international exhibitions such as the Boao Forum for Asia Global Health Forum and the International Biomedical Industry Innovation Beijing Forum as' windows', take the advantages of the chemical industry as cooperation opportunities, communicate face-to-face with enterprises, and lay a good foundation for future cooperation. "The person in charge of Beijing Economic and Technological Development Zone said that recently, global leading pharmaceutical companies such as Eli Lilly and Pfizer have successively announced the establishment of new research and development innovation institutions in Yizhuang, Beijing. Yizhuang will continue to create an optimized business environment, create an open and inclusive industrial ecology, support multinational pharmaceutical companies to choose Beijing and invest in Yizhuang, and jointly draw a new blueprint for the development of the pharmaceutical and health industry.

Furthermore, on the 2nd, Minister of Commerce Wang Wentao met with Frederick Uday, Chairman of the Board of Directors of Sanofi Group, in Beijing. Both sides exchanged views on topics such as the development of Sanofi Group's business in China.

Source: https://pharm.jgvogel.cn/c1468065.shtml